Real-world efficacy of atezolizumab for advanced urinary tract cancer


  • Dawn O'Shea
  • Univadis Medical News
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Results from the SAUL study have demonstrated the real-world safety and efficacy of atezolizumab in the treatment of locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract.

The multi-national single-arm safety trial evaluated atezolizumab in a broad, pre-treated population, including patients ineligible for the pivotal IMvigor211 phase 3 trial of atezolizumab.

Between November 2016 and March 2018, 1,004 patients with locally advanced or metastatic urothelial or non-urothelial urinary tract carcinoma who experienced progression during or after one to three prior therapies for inoperable, locally advanced or metastatic disease were enrolled.

Median follow-up was 12.7 months. The median treatment duration was 2.8 months, ranging from 0 to 19 months.

Median overall survival (OS) was 8.7 (95% CI 7.8-9.9) months. The six-month OS rate was 60 per cent (95% CI 57%-63%), median progression-free survival was 2.2 (95% CI 2.1-2.4) months and the overall response rate was 13 per cent (95% CI 11%-16%; 3% complete responses).

Eight per cent discontinued treatment because of toxicity. Grade ≥3 adverse events occurred in 45 per cent of patients. The most common grade ≥3 treatment-related adverse events were fatigue, asthenia, colitis and hypertension.

The findings, published in European Urology, are consistent with previous pivotal trials in urothelial carcinoma.